CYP-001
Phase 1Biologic
CYP-001 is one of 39 biologic programs targeting Respiratory Failure. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
66 competitors in Respiratory Failure
#DrugCompanyPhaseTrials
1Leukine
SanofiApproved
Diamox
TevaApproved
Amidate
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
Duragesic
CCephalon
Approved
Merrem
BB. Braun Medical Inc.
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Inomax
MMallinckrodt
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Ketalar
AAultman Health Foundation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CYP-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- CCynata Therapeutics Limited